TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05466539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
Study: NCT05269303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Live With Wearable Monitoring Device program
Description: The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
Study: NCT05610943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided quadratus lumborum nerve block
Description: The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block
Description: The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
Study: NCT04756570

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Group 1
Description: Individuals in this group will receive one session of robotic rehabilitation in addition to conventional therapy each week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Group 2
Description: Individuals in this group will receive two sessions of robotic rehabilitation in addition to conventional therapy each week
Study: NCT05420922

Intervention type: DRUG
Intervention: Lenvatinib Oral Product
Description: Lenvatinib or Sorafenib

Intervention type: DRUG
Intervention: Lenvatinib Oral Product
Description: Lenvatinib or Sorafenib

Intervention type: DRUG
Intervention: PD-1 inhibitor
Description: Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1

Intervention type: DRUG
Intervention: PD-1 inhibitor
Description: Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1

Intervention type: PROCEDURE
Intervention: Local treatment
Description: Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.

Intervention type: PROCEDURE
Intervention: Local treatment
Description: Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
Study: NCT05585138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: segmental breathing exercise
Description: Group-A (interventional group) will receive segmental breathing exercises and deep breathing. segmental breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and in exhalation therapist will apply pressure on intercostal spaces at apical, lateral and posterior for one month 5 days a week and 2 sessions per day for 15 minutes for each patient. conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day.
Study: NCT05764538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
Study: NCT05585138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep breathing
Description: conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep breathing
Description: conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
Study: NCT05095363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCplanner
Description: A mobile app platform that will display participant survey results to clinicians to facilitate communication on specific needs as well as provide resources on advance care planning to participants.
Study: NCT05643820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 5% topical lotion
Description: patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
Study: NCT05893199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical monitoring using the Ti.Care app (https://ti.care/es)
Description: Clinical monitoring using the Ti.Care app (https://ti.care/es)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: usual follow-up in primary care both arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: usual follow-up in primary care both arms
Study: NCT05694403

Intervention type: OTHER
Intervention: Survey
Description: Questionnaire

Intervention type: OTHER
Intervention: Survey
Description: Questionnaire
Study: NCT05876611

Intervention type: DEVICE
Intervention: New type of self stabilizing atlantoaxial fusion cage
Description: Using the above-mentioned new fusion cage for the treatment of atlantoaxial dislocation
Study: NCT06645574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The multidisciplinary preventive approach among young people involved in intensive sports activities. Athlete will see doctor and physiotherapist.
Description: Athletes will have 2 times per years prevention examination:~* A standard medical examination~* A physiotherapy assessment with strength assessment~* They will complete psychometric evaluation self-questionnaires
Study: NCT06647212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: introducing breathing exercises with the harmonica
Description: In addition to regular breathing exercises, participants will perform harmonica exercises
Study: NCT06645769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Phenylbutyrate
Description: will be compared to placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will be compared to NaPB
Study: NCT05096468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine and pregabalin
Description: * Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline and placebo capsule
Description: * Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours
Study: NCT06000982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTCY
Description: PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTCY
Description: PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis
Study: NCT05232474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KomPas+
Description: KomPas+ is a guideline-based clinical decision support system. With KomPas+, the aim is to integrate KomPas with the guideline recommendations for the conservative treatment process of patients with intermittent claudication. KomPas+ is a web-based tool, aimed to facilitate person-centered and participatory healthcare. Therapists have access to a tool that will help, for example, to improve consistency between patient-specific goals and the treatment plan. Using KomPas+, therapists are encouraged to discuss choices in the treatment plan with the patient. It is expected that the included topics in KomPas+ will not be burdensome for both patients and therapists. Topics to discuss are, for example, Frequency, Intensity, Time and Type (FITT) for drawing up a training schedule. KomPas+ is meant to facilitate therapists and patients in the SDM process. It does not force patients to take part in the SDM process against their will.

Intervention type: DEVICE
Group type: OTHER
Intervention: KomPas
Description: KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KomPas
Description: KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.
Study: NCT05552222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered as SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Daratumumab will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered as SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered either orally or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as SC injection.
Study: NCT06382909

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammatory level
Description: Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inflammatory level
Description: Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inflammatory level
Description: Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive assessment
Description: Neurological assessment Psychiatric assessment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive assessment
Description: Neurological assessment Psychiatric assessment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive assessment
Description: Neurological assessment Psychiatric assessment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pedagogical assessment
Description: Sociopedagogical assessment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pedagogical assessment
Description: Sociopedagogical assessment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pedagogical assessment
Description: Sociopedagogical assessment
Study: NCT06512103

Intervention type: DIAGNOSTIC_TEST
Intervention: Apical periodontitis group
Description: Radiography of the patients were taken. Blood samples and gingival crevicular fluid samples were collected from those patient

Intervention type: DIAGNOSTIC_TEST
Intervention: Apical periodontitis group
Description: Radiography of the patients were taken. Blood samples and gingival crevicular fluid samples were collected from those patient
Study: NCT04297618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiidra
Description: Xiidra (lifitegrast 5% ophthalmic solution)
Study: NCT06619730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sedline Brain Function Monitor
Description: The anesthesia provider will use the Sedline Brain Function Monitor information to affect their anesthetic dosing.
Study: NCT06617104

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06618105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
Description: Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Placebo
Description: Matching Placebo of T inhalation aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Placebo
Description: Matching Placebo of T inhalation aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Placebo
Description: Matching Placebo of T inhalation aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Test Placebo
Description: Matching Placebo of T inhalation aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Placebo
Description: Matching Placebo of R inhalation aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Placebo
Description: Matching Placebo of R inhalation aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reference Placebo
Description: Matching Placebo of R inhalation aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
Description: Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations
Description: Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.)
Study: NCT06624046

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep stability intervention
Description: The sleep stability intervention will consist of three theory-based intervention components our team has developed and used in prior interventions: 1) self-monitoring using a wearable sleep tracker (Fitbit). This is well-liked by participants and increases awareness of their sleep goals. 2) Accountability coaching via weekly check-ins and daily monitoring of participants' wearable sleep tracking data and a coaching protocol.
Study: NCT06625502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-Affirming Racial Equity Framework
Description: The CARE framework is a process-focused, protocol- based, and modular approach to culturally-affirming mental health care for racial and ethnic minority populations to promote racial equity. It focuses on cultivating the cross-racial/cross-cultural therapeutic alliance in the first 3-4 treatment sessions, the critical window for engaging patients in care. Target processes include transparent communication, client-centeredness, client activation, and a culturally-affirming and anti-oppressive approach to assessment and treatment planning. Case conceptualization and treatment planning is collaborative, and guided by the individual clinician based on evidence-based treatments. The therapist receives ongoing biweekly supervision in Alliance-Focused Training and cultural consultation sessions with a cultural expert.
Study: NCT06625450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib alone will be continued at a dose of 11 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib plus mesalamine
Description: Both tofacitinib 11 mg once a day and mesalamine will be continued
Study: NCT06624852

Intervention type: OTHER
Intervention: Screening for coronary artery revascularization based on TMT-ECG
Description: Screening for coronary artery revascularization based on TMT-ECG with and without the assistance of PROPECG-TMT

Intervention type: OTHER
Intervention: Screening for coronary artery revascularization based on TMT-ECG
Description: Screening for coronary artery revascularization based on TMT-ECG with and without the assistance of PROPECG-TMT
Study: NCT05890963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: ART is a combination of three or more drugs from different classes of antiretroviral medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: 10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: 10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: 10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: 10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.